CURRICULUM VITAE FOR R. TIMOTHY WEBB, M.D., F.A.C.P.

Office Address:
Genesis Cancer Center
One Mercy Lane, Suite 303
Hot Springs, AR 71913

EDUCATION:
1973: Lakeside High School, Hot Springs, AR
1973-1974: Auburn University, Auburn, AL
1974-1977: University of Arkansas at Fayetteville, B.A. Chemistry
1977-1978: University of Arkansas at Fayetteville, Graduate Program in Nuclear Chemistry
1978-1982: University of Arkansas for Medical Sciences, M.D.
1982-1983: Internship, Internal Medicine
University Hospital of Arkansas - Little Rock
1983-1985: Residency, Internal Medicine, University Hospital of Arkansas - Little Rock
1985-1988: Fellowship, Hematology/Oncology, University Hospital of Arkansas - Little Rock

BOARD CERTIFICATION/LICENSURE:
1982: Arkansas Medical License C-6126
1985: American Board of Internal Medicine - Internal Medicine #102653
1993: American Board of Internal Medicine - Oncology

PROFESSIONAL SOCIETIES:
Fellow, American College of Physicians
Member, American College of Physician Executives
Member, American Medical Association
Member, American Society of Clinical Oncology
Member, American Society of Internal Medicine
Member, Arkansas Medical Society
Delegate to State Convention for Garland County 1993, 1994
Member, Southern Medical Association
Founding Member, Southern Association of Oncology
Member, Arkansas Blood Club
President, Arkansas Clinical Oncology Association 2003 – 2005
Symposium Program Committee, American Society of Breast Disease 2003 – 2006
Governor’s Council, American College of Physicians 2003- 2006

HONORS:
1981: Lange Book Award for Scholastic Achievement
1985: National American College of Physicians Abstract Contest Winner
1985: ACP Associate National Abstract Contest
1985-1986: American Cancer Society Clinical Fellowship
1989: American Cancer Society Medical Volunteer of the Year (Arkansas)
1988-1991: Physician’s Recognition Award of the AMA
1992-1995: Physician’s Recognition Award of the AMA
1995: Fellow of the American College of Physicians
1997: Appointed by Arkansas Governor Mike Huckabee to the Oversight Committee for Breast Cancer Research
2003: Appointed to the Arkansas State Board of Public Health

PROFESSIONAL EXPERIENCE:
1988-present
Genesis Cancer Center (Central Arkansas Hematology and
Oncology Clinic, P.A. dba Genesis Cancer Center)

Staff-
St. Joseph’s Regional Health Center
Patient Support Committee, 1988-1992, Chairman 1990
Tumor Control Committee, 1992-present
Chief of Medicine, 1993, 1995
Quality Management Committee, 1994

Staff-
National Park Medical Center
ICU Committee, 1988-present
Associate Chief of Medicine, 1996
Executive Committee Secretary, 1997
Associate Chief of Medicine, 1999

Staff-
Levi Hospital
CGOP for Southwest Oncology Group (SWOG), 1992-present
Principal Investigator for Advanced Cancer Technologies, 1992-1994
Registered Investigator affiliated with the National Cancer Institute, 1991-present
Registered Investigator with Eastern Cooperative Oncology Group (ECOG), 1996-1999
Subinvestigator with Response Oncology, Inc., 1998-present

COMMUNITY ACTIVITIES:
Garland County Chapter of the American Cancer Society, 1988-present, President 1989-1991
Arkansas Division of American Cancer Society Board Member 1992-1995
Chairman, Professional Education Garland County Chapter of the American CancerSociety, 1992-1995
Member, Garland County Fifty for the Future, 1993-1995
Board of Stewards, First United Methodist Church, 1992-1999
Chairman, First United Methodist Church Building Committee, 1994-1996
Member, Chamber of Commerce, 1994-present

PUBLICATIONS:
Webb T, Hiller C, Beaton N, Wilson F. Shifting Granuloma: A Sign of Lobar Collapse. Chest, 4; 1984, 55-57.

Janati A, Webb RT. Neuroleptic Malignant Syndrome with Bromocriptine - A Study of Four Cases. Southern Medical Journal, December 1986, 444-448.

Hutchins L, Webb RT, Ortego T, Lang N, Navab F. Hepatic Artery Chemotherapy Infusion Catheter Associated with a Penetrating Duodenal Ulcer: Successful Conservative Medical Management. Accepted for publication by the Journal of Clinical Gastroenterology, January 1988.

Webb RT, Kletzel M. Extraskeletal Mesenchymal Chondrosarcoma of the Neck.

Twice monthly newspaper column “Doctors and Sense” for the Sentinel Record newspaper on aspects of cancer and treatment, 1995-1997, articles by request 1998-present.

Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S., Bachinsky ME, Dirlam NL, Stack CB, and Silberman S. Randomized Phase II Study of the Neurokinin-1 Antagonist CJ-11, 974 in the Control of Cisplatin-Induced Emesis. Journal of Clinical Oncology, January 1999; Vol 17, No 1; 338-343.

PRESENTATIONS:
Webb RT, Janati A. Successful treatment of neuroleptic malignant syndrome with bromocriptine - a study of four cases. Abstract presented at the American College of Physicians meeting, Washington, D.C., March 1985.

Lung Cancer, yearly lecture to second year medical school class in Clinical Correlates course at the University of Arkansas for Medical Sciences.

Megaloblastic anemia, yearly lecture to second year medical school class in Clinical Correlates course at the University of Arkansas for Medical Sciences.

Malignancies associated with the HTLV III virus, January 1986, CARTI Tumor Board Conference, Little Rock, AR.

Lymphocyte function, lecture to Hematology Conference, May 1987.

Lead poisoning, hematological effects, Subspecialty Conference, January 1988.

Update on breast cancer therapy, Department of Surgery meeting, St. Joseph’s Regional Health Center, October 1988.

Breast cancer update: current use of adjuvant chemotherapy in breast cancer, June 1991.

Cancer Chemotherapy Course, Oncology Nursing Society (Garland County chapter), March 1992.

Weekly Tumor Board Conference Moderator/Presenter, St. Joseph’s Regional Health Center, May 1992-present.

Diagnosis and treatment of breast cancer seminar, American Cancer Society, St. Joseph’s Regional Health Center, April 1993.

Biologic modifiers in the treatment of malignancy, Oncology Nursing Society, St. Joseph’s Regional Health Center, June 1993.

Diet and cancer, Greater Kiwanis Club of Hot Springs Village, April 1994.

Genetics and cancer, United Methodist Men of the Church, June 1994.

Nursing aspects of chemotherapy, nursing staff of National Park Medical Center, July-August 1996.

Nonsurgical management of breast cancer, National Park Medical Center, October 1996.

Clinical trials training video for Pfizer, Inc., January 1999.

“Refractory Anemia,” American College of Physicians Arkansas Chapter Meeting, October 2002.

LISTING OF PROTOCOLS FOR DR. WEBB

NOVARTIS – ZOLEDRONATE PROTOCOL CGP-42446-03-011
“A Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients with any Cancer with Bone Metastases Other than Breast Cancer, Multiple Myeloma or Prostate Cancer”

NOVARTIS – ZOLEDRONATE PROTOCOL 011E
Extension study of CGP-42446-03-011

RESPONSE Breast Trial

LILLY-BREAST B9E-MC-JHQG
“A Phase 3 Study of Gemcitabine plus Paclitaxel vs. Paclitaxel in Patients with Unresectable, Locally Recurrent or Metastatic Breast Cancer”

SWOG-Melanoma 9512
“A Phase III Study of Adjuvant Ganglioside Vaccination GM2-KLH/QS-21 Therapy vs. High-Dose Interferon Alpha-2b (Intron A) for High Risk Melanoma (T4 > 4 mm Primary or Regional Lymph Node Metastasis)”

SWOG-Prostate 9916
“Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III”

SWOG-N9841
“A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatine (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients with Advanced Colorectal Carcinoma Previously Treated with 5-FU”

SWOG-G0137
“A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women with Stage I or II Endometrial Adenocarcinoma”

ILEX-AESGEN: Oral Mucositis Protocol 99-1401
A Randomized, Double-Blind, Multicenter, Parallel Group, Double Placebo-Controlled Study of the Efficacy and Safety of AES0014 (L-glutamine Oral Suspension) in Reducing the Severity of Oral Mucositis/Stomatitis Associated with Cancer Chemotherapy”

ORTHO BIOTECH – PROCRIT STUDY: PROO-27-012
“An Open-Label Study of PROCRIT® (Epoetin alfa) In Women Under-going Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer”

PADDOCK – PDA: Oral Candidiasis Protocol PAD801E
“Single-Blind, Randomized, Multi-Center Study of the Clinical Equivalence and Safety of a Generic Clotrimazole Troche vs. Myclex Troches in Subjects With a Diagnosis of Oral Candidiasis”

MERCK ANTIEMETIC PROTOCOL – Protocol 044-01 MK-0869
“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of MK-0869 for the Prevention of Chemotherapy-Induced Emesis Associated with Moderately Emetogenic Chemotherapy”

INGENIX SURVEILLANCE STUDY – GEMZAR/CARBO 238-09-00 Lung trial

LILLY LUNG – ALIMTA H3E-MC-JMEI
“A Phase 3 Trial of ALIMTA vs Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Were Previously Treated with Chemotherapy”

PPD TAX/MEN.12
“A Multicenter, Phase III Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol® (Paclitaxel) and Carboplatin (Paraplatin®) Regiman Versus Standard Taxol and Carboplatin Administered Every Three Weeks”

HER2 – H2251n Breast trial

TRAVIOTA
“Trastuzumab (Herceptin) and Either Vinorelbine (Navelbine) or Taxane-based Chemotherapy in Patients with HER 2 Overexpressing Metastatic Breast Cancer: A Randomized Phase III Study – the Traviota Study”

VIRULIZIN - Compassionate Use - Pancreatic Trial

ARK 201 – CACHEXIA STUDY
“A Phase III, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose-Titration Study of Imidapril Hydrochloride (EG006) in the Treatment of Cancer Cachexia”

MERCK ANTIEMETIC: MERCK PROTOCOL 071-00/EME528
“A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy”

ANC NEUTROPENIA STUDY PHASE I
“ANC Study Group Registry: A Prospective Study of Neutropenic Complications”

ANC NEUTROPENIA STUDY PHASE II
“ANC Study Group Registry: A prospective Study of Neutropenic Complications”

ORTHO RAPID STUDY #PRO2-27-018
“Retrospective Review of Alternate Procrit® Dosing in Patients with Chemotherapy Related Anemia”

LILLY LUNG – ISIS: PROTOCOL H7X-MC-JVAA
“A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer”

LILLY ALIMTA – MESOTHELIOMA

AMGEN 20010101 ANEMIA STUDY
“A Randomized, Open-Label Study of darbepoetin alfa (Novel Erythropoiesis Stimulating Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multi-cycle Chemotherapy”

AMGEN SOAR 20000220 ANEMIA STUDY-NESP
“An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and NESP”

AMGEN SURPASS ANEMIA STUDY: PROTOCOL 20020132-NESP
“A Study to Assess Symptom Burden In Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp™”

AMGEN PROTOCOL 20030125: ANEMIA STUDY
“A Randomized, Open-Label, Multicenter Study of darbepoetin alfa Administered Once Every 2 Weeks (Q2W) Compared with rHuEPO Administered Once Every Week (QW) for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multi-cycle Chemotherapy”

AMGEN PROTOCOL 20030232: ANEMIA STUDY
“A Randomized, Double-blind, Placebo-controlled Study of darbepoetin alfa for the Treatment of Anemia in Subjects with Non-myeloid Malignancies Receiving Multicycle Chemotherapy”

MDS ORTHO PRO3-27-064: ANEMIA STUDY
“A Randomized, Open-Label Study Of PROCRIT® (Epoetin Alfa) Initiated At 40,000 Units Every Week Versus 80,000 Units Every Two Weeks In Anemic Patients With Cancer Receiving Chemotherapy”

NATIONAL PATIENT IMPACT INITIATIVE - (ACORN SURVEY)
“National Patient Impact Initiative: The Impact of Medical Visits on Time and Activities of Cancer Patients”

PROTOCOL SBVFCIA0401 – (ACORN ANEMIA AUDIT)
“Determining the Status of Anemia Management in Community Oncology”

Amgen ACCEPT Protocol 20040105 (Post-Neulasta Launch 2003 Chart Review)

LILLY BREAST – B9E-US-S188(b)
“Randomized Trial Of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine In Metastatic Breast Cancer In 1st and 2nd Line Patients”

ACORN DOSE DENSE ANEMIA STUDY – ALSSCIA0401
“Minimizing Chemotherapy-Induced Anemia (CIA) with Darbepoetin Alfa in Patients with Breast Cancer Receiving Adjuvant Dose Dense Chemotherapy”